Zacks: Analysts Anticipate Kodiak Sciences Inc. (NASDAQ:KOD) Will Announce Earnings of -$1.61 Per Share

Wall Street brokerages expect that Kodiak Sciences Inc. (NASDAQ:KODGet Rating) will post earnings per share (EPS) of ($1.61) for the current fiscal quarter, according to Zacks Investment Research. Zero analysts have provided estimates for Kodiak Sciences’ earnings. The lowest EPS estimate is ($1.97) and the highest is ($0.81). Kodiak Sciences reported earnings per share of ($1.08) during the same quarter last year, which would suggest a negative year-over-year growth rate of 49.1%. The company is expected to report its next quarterly earnings report on Monday, January 1st.

On average, analysts expect that Kodiak Sciences will report full-year earnings of ($6.64) per share for the current financial year, with EPS estimates ranging from ($8.52) to ($3.30). For the next year, analysts expect that the firm will post earnings of ($4.92) per share, with EPS estimates ranging from ($7.74) to ($2.93). Zacks Investment Research’s EPS averages are an average based on a survey of sell-side analysts that cover Kodiak Sciences.

Kodiak Sciences (NASDAQ:KODGet Rating) last announced its quarterly earnings data on Tuesday, May 10th. The company reported ($1.83) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.51) by ($0.32). During the same quarter in the previous year, the company posted ($0.98) earnings per share.

Several equities research analysts have issued reports on the stock. The Goldman Sachs Group began coverage on shares of Kodiak Sciences in a research report on Friday, February 11th. They set a “buy” rating and a $70.00 target price for the company. Roth Capital cut their price objective on Kodiak Sciences from $149.00 to $75.00 in a research report on Monday, February 28th. Barclays decreased their price target on shares of Kodiak Sciences from $81.00 to $50.00 and set an “underweight” rating for the company in a research note on Monday, February 7th. Chardan Capital reissued a “buy” rating on shares of Kodiak Sciences in a research report on Monday, April 11th. Finally, Citigroup dropped their price target on Kodiak Sciences from $70.00 to $12.00 and set a “neutral” rating on the stock in a research report on Thursday, February 24th. One analyst has rated the stock with a sell rating, four have issued a hold rating and two have issued a buy rating to the company. According to data from MarketBeat.com, Kodiak Sciences currently has an average rating of “Hold” and an average price target of $45.33.

Shares of Kodiak Sciences stock traded up $1.19 on Tuesday, reaching $9.03. The stock had a trading volume of 69,641 shares, compared to its average volume of 1,054,977. Kodiak Sciences has a 1 year low of $4.90 and a 1 year high of $26.39. The company has a market cap of $469.11 million, a P/E ratio of -1.51 and a beta of 1.97. The business’s 50 day moving average is $6.70 and its two-hundred day moving average is $39.15.

In other news, Director Bros. Advisors Lp Baker bought 122,100 shares of the stock in a transaction on Monday, May 16th. The stock was acquired at an average cost of $5.72 per share, for a total transaction of $698,412.00. Following the acquisition, the director now owns 14,843,809 shares of the company’s stock, valued at $84,906,587.48. The acquisition was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Over the last ninety days, insiders have acquired 816,015 shares of company stock valued at $5,670,730. 39.70% of the stock is currently owned by corporate insiders.

A number of large investors have recently modified their holdings of the stock. BlackRock Inc. increased its holdings in shares of Kodiak Sciences by 20.5% during the first quarter. BlackRock Inc. now owns 3,435,960 shares of the company’s stock valued at $26,526,000 after acquiring an additional 584,762 shares in the last quarter. Acadian Asset Management LLC purchased a new position in shares of Kodiak Sciences in the first quarter worth $3,603,000. Krensavage Asset Management LLC acquired a new stake in shares of Kodiak Sciences during the first quarter worth $3,479,000. Walleye Capital LLC grew its holdings in shares of Kodiak Sciences by 1,904.5% during the first quarter. Walleye Capital LLC now owns 356,093 shares of the company’s stock valued at $2,749,000 after buying an additional 338,328 shares during the last quarter. Finally, Graham Capital Management L.P. acquired a new position in shares of Kodiak Sciences in the 1st quarter valued at $2,282,000. 69.80% of the stock is owned by institutional investors.

About Kodiak Sciences (Get Rating)

Kodiak Sciences Inc, a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is KSI-301, an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as for the treatment of diabetic macular edema, naïve macular edema due to retinal vein occlusion, and non-proliferative diabetic retinopathy.

Featured Articles

Get a free copy of the Zacks research report on Kodiak Sciences (KOD)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Kodiak Sciences (NASDAQ:KOD)

Want More Great Investing Ideas?

Receive News & Ratings for Kodiak Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kodiak Sciences and related companies with MarketBeat.com's FREE daily email newsletter.